The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On ...
Proposal Delivers Immediate, Compelling and Certain Cash Value for Vanda Shareholders with a Highly Attractive Premium of 80% to Vanda’s Closing Share Price on October 11, 2024 Urges Vanda ...
WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for ...
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results